Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$103.02 USD
+1.64 (1.62%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $103.04 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AXSM 103.02 +1.64(1.62%)
Will AXSM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study
Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Other News for AXSM
A Look at Axsome Therapeutics's Upcoming Earnings Report
Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy
Axsome Therapeutics Breaks Below 200-Day Moving Average - Notable for AXSM
Axsome Therapeutics (AXSM) to Highlight CNS Pipeline at R&D Day | AXSM Stock News
Axsome Therapeutics Inc (AXSM) Hosts Frontiers in Brain Health R&D Day | AXSM stock news